Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
NCT04251533 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2026-09-10 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.” | Open Targets' class: insufficient enrollment | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-07Results posted on the registry: M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-07-07Also stopped (terminated): M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision